<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990443</url>
  </required_header>
  <id_info>
    <org_study_id>C38072/1107</org_study_id>
    <nct_id>NCT01990443</nct_id>
  </id_info>
  <brief_title>Absolute Bioavailability of Reslizumab in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-Label, Parallel-Group, Single-Dose Study to Characterize the Absolute Bioavailability of Reslizumab (220 mg) Following Subcutaneous Administration to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the absolute bioavailability of reslizumab&#xD;
      following administration of a single subcutaneous (sc) dose to healthy non-Japanese&#xD;
      participants&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to assess the pharmacokinetics, safety and tolerability,&#xD;
      immunogenicity, and pharmacodynamics of reslizumab&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute bioavailability</measure>
    <time_frame>From baseline to Day 140</time_frame>
    <description>Absolute bioavailability calculated as (AUC0-∞)sc/(AUC0-∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum drug concentration (Cmax)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum drug concentration (tmax)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0 to the time of the last measurable drug concentration (AUC0-t)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage extrapolation</measure>
    <time_frame>From baseline to Day 140</time_frame>
    <description>Percentage extrapolation will be calculated as (AUC0-∞-AUC0-t)/(AUC0-∞)x100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent serum terminal elimination rate constant (λz)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated elimination half-life (t½)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum clearance (CL)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Eosinophils Levels</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-reslizumab antibodies</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participants with Adverse Events</measure>
    <time_frame>From signing of consent form to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples for measurement of Anti-reslizumab antibodies</measure>
    <time_frame>Baseline, days 14, 28, 84, 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum drug concentration by time curve from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Absolute Bioavailability</condition>
  <arm_group>
    <arm_group_label>Reslizumab IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reslizumab 220-mg administered Intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reslizumab SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reslizumab 220-mg administered Subcutaneously (SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reslizumab IV</intervention_name>
    <description>Reslizumab 220-mg intravenous (IV)</description>
    <arm_group_label>Reslizumab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reslizumab SC</intervention_name>
    <description>Reslizumab 220 mg administered subcutaneous (SC)</description>
    <arm_group_label>Reslizumab SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for Inclusion: Subjects may be included in the study if they meet all of the&#xD;
        following criteria:&#xD;
&#xD;
        All Subjects&#xD;
&#xD;
          1. Written informed consent is obtained.&#xD;
&#xD;
          2. The subject can read, speak, and write in English or Japanese (as applicable to the&#xD;
             respective enrollment group).&#xD;
&#xD;
          3. The subject is in good health as determined by medical and psychiatric history,&#xD;
             physical examination, brief neurologic examination, ECG, serum chemistry, hematology,&#xD;
             urinalysis, and serology.&#xD;
&#xD;
          4. The subject, if a woman, is surgically sterile, 2 years postmenopausal, or, if of&#xD;
             childbearing potential, is using a medically accepted method of contraception, and&#xD;
             agrees to continued use of this method for the duration of the study and for 30 days&#xD;
             after completion of the study. Acceptable methods of contraception include abstinence&#xD;
             or an intrauterine device (known to have a failure rate of less than 1% per year).&#xD;
&#xD;
          5. The subject must be willing and able to comply with study restrictions and to remain&#xD;
             at the clinic for the required duration at each visit. Non-Japanese Subjects&#xD;
&#xD;
          6. The subject has Caucasian parents and grandparents.&#xD;
&#xD;
          7. The subject is a man or woman 18 through 45 years of age with a body mass index (BMI)&#xD;
             of 20.0 to 30.0 kg/m2, inclusive (Appendix A). Note: At least half of the subjects&#xD;
             enrolled into each treatment group must be within the more stringent age and weight&#xD;
             criteria noted below for Japanese subjects.&#xD;
&#xD;
             Also, every effort should be made to enroll an approximately equal number of men and&#xD;
             women.&#xD;
&#xD;
             Japanese Subjects&#xD;
&#xD;
          8. The subject is a man or woman 20 through 45 years of age weighing 50 through 80 kg&#xD;
             with a BMI of less than 28.0 kg/m2. Note: Every effort should be made to enroll an&#xD;
             approximately equal number of men and women.&#xD;
&#xD;
          9. The subject was born in Japan.&#xD;
&#xD;
         10. The subject has Japanese parents and grandparents.&#xD;
&#xD;
         11. The subject has lived less than 5 years outside Japan.&#xD;
&#xD;
         12. The subject has a Japanese passport.&#xD;
&#xD;
         13. The subject has no plans to leave the US until at least 1 week after the end of the&#xD;
             study.&#xD;
&#xD;
        Criteria for Exclusion: Subjects will be excluded from participating in this study if they&#xD;
        meet 1 or more of the following criteria:&#xD;
&#xD;
          1. The subject has any clinically significant uncontrolled medical conditions (treated or&#xD;
             untreated).&#xD;
&#xD;
          2. The subject has a clinically significant deviation from normal in ECG, physical&#xD;
             examination, or brief neurologic examination findings, as determined by the&#xD;
             investigator or the medical monitor.&#xD;
&#xD;
          3. The subject is a pregnant or lactating woman. (Any women becoming pregnant during the&#xD;
             study will be withdrawn from the study.)&#xD;
&#xD;
          4. The subject has any disorder that may interfere with drug absorption, distribution,&#xD;
             metabolism, or excretion (including gastrointestinal surgery; a history of&#xD;
             appendectomy is allowed).&#xD;
&#xD;
          5. The subject has received reslizumab in a previous study.&#xD;
&#xD;
          6. The subject has received an immunosuppressant drug or anti-interleukin-5 (anti-IL-5)&#xD;
             antibody within 6 months before the dose of study drug.&#xD;
&#xD;
          7. The subject has received any investigational drug (non-biologic) within 30 days or 5&#xD;
             half-lives (whichever is longer) before the dose of study drug, or in the case of a&#xD;
             new chemical entity, 3 months or 5 half-lives (whichever is longer) before the dose of&#xD;
             study drug.&#xD;
&#xD;
          8. The subject has participated in any investigative biologics study within 6 months or 5&#xD;
             half-lives (whichever is longer) before the dose of study drug.&#xD;
&#xD;
          9. The subject has a known or suspected hypersensitivity or idiosyncratic reaction to&#xD;
             anti-IL-5 antibodies, any compound present in the study drug, or monoclonal&#xD;
             antibodies.&#xD;
&#xD;
         10. The subject has a history of any clinically important drug, vaccine and/or other&#xD;
             allergies or there is indication of potential for allergic reactions. Pharmacokinetic&#xD;
             Study-Healthy Subjects Clinical Study Protocol Study C38072/1107 8&#xD;
&#xD;
         11. The subject has received immunization with a live vaccine within 3 months prior to the&#xD;
             dose of study drug or has immunization with a live or live attenuated vaccine planned&#xD;
             within 3 months after the last dose of study drug.&#xD;
&#xD;
         12. The subject had or was suspected of having a parasitic infestation/infection within 6&#xD;
             months before the dose of study drug.&#xD;
&#xD;
         13. The subject has used any vitamins within 2 weeks before the dose of study drug or has&#xD;
             used any systemic or topical prescription, or nonprescription (over-the-counter [OTC])&#xD;
             medication (except acetaminophen or ibuprofen) within 2 weeks or 5 half-lives&#xD;
             (whichever is longer) before the dose of study drug.&#xD;
&#xD;
         14. The subject has used any herbal or nutritional supplements within 2 weeks before the&#xD;
             dose of study drug.&#xD;
&#xD;
         15. The subject has donated blood or has a history of significant blood loss within 56&#xD;
             days prior to the dose of study drug.&#xD;
&#xD;
         16. The subject has donated plasma within 7 days prior to the dose of study drug.&#xD;
&#xD;
         17. The subject has, after resting for 5 minutes, elevated blood pressure (defined as&#xD;
             seated systolic blood pressure of more than 140 mm Hg and/or seated diastolic blood&#xD;
             pressure of more than 90 mm Hg), or low blood pressure (defined as seated systolic&#xD;
             blood pressure of less than 90 mm Hg and/or seated diastolic blood pressure of less&#xD;
             than 45 mm Hg). (Only 2 rechecks of the subject's blood pressure are permitted for&#xD;
             eligibility purposes.)&#xD;
&#xD;
         18. The subject has, after resting for 5 minutes, a seated pulse of less than 45 or more&#xD;
             than 90 beats per minute (bpm). (Only 2 rechecks of the subject's pulse are permitted&#xD;
             for eligibility purposes.)&#xD;
&#xD;
         19. The subject has, within the past 2 years, habitually consumed more than 21 units of&#xD;
             alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse&#xD;
             as defined by the Diagnostic and Statistical Manual of Mental Disorders of the&#xD;
             American Psychiatric Association, Fourth Edition, Text Revision (DSM-IV-TR) (American&#xD;
             Psychiatric Association 2000). Note: For the purpose of this study, a unit of alcohol&#xD;
             is equal to 1 ounce of hard liquor, 5 ounces of wine, or 8 ounces of beer.&#xD;
&#xD;
         20. The subject has a positive urine drug screen (UDS) or alcohol test result.&#xD;
&#xD;
         21. The subject has a clinical laboratory test value(s) outside the range(s) specified&#xD;
             below, or any other clinically significant laboratory abnormality as determined by the&#xD;
             investigator or medical monitor:&#xD;
&#xD;
               -  hemoglobin value of less than 12 g/dL&#xD;
&#xD;
               -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 2&#xD;
                  times the upper limit of the normal range (ULN)&#xD;
&#xD;
               -  total bilirubin more than 25.7 μmol/L (1.5 mg/dL)&#xD;
&#xD;
         22. The subject has a positive test result for human immunodeficiency virus (HIV),&#xD;
             hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C.&#xD;
&#xD;
         23. The subject has, within 14 days before the dose of study drug, a clinically&#xD;
             significant excessive consumption of coffee, tea, or other caffeine-containing&#xD;
             beverages or food (ie, 600 mg/day of caffeine, 5 or more cups of coffee/day, or 10 or&#xD;
             more cups of tea/day), or a combination of any of these beverages or foods.&#xD;
&#xD;
         24. The subject is a user or former user of nicotine-containing products (including but&#xD;
             not limited to cigarettes, cigars, and chewing or dipping tobacco) who stopped use or&#xD;
             consumption (ie, smoking, chewing, or pinching) of these nicotine-containing products&#xD;
             less than 12 months before study drug administration or is using or has used topical&#xD;
             or oral nicotine preparations for smoking cessation within the past 3 months before&#xD;
             study drug administration.&#xD;
&#xD;
         25. The subject has had, within 4 weeks before the dose of study drug, a clinically&#xD;
             significant illness, or within 1 week before the dose of study drug, any acute illness&#xD;
             or, at screening or on the day before the first dose of study drug, has symptoms of&#xD;
             any clinically significant or acute illness.&#xD;
&#xD;
         26. The subject has significant active infection (acute or chronic) within 4 weeks before&#xD;
             the dose of study drug. aa. The investigator feels that the subject should not be&#xD;
             enrolled in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Teva Investigational Site 10567</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reslizumab</keyword>
  <keyword>monoclonal antibody</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reslizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

